|1.||Field, Martha S: 1 article (01/2009)|
|2.||Anguera, Montserrat C: 1 article (01/2009)|
|3.||Stover, Patrick J: 1 article (01/2009)|
|4.||Page, Rodney: 1 article (01/2009)|
|5.||Yoshida, H: 1 article (11/2003)|
|6.||Nakamura, M: 1 article (11/2003)|
|7.||Komiya, S: 1 article (11/2003)|
|8.||Matsuyama, T: 1 article (11/2003)|
|9.||Nagayoshi, R: 1 article (11/2003)|
|10.||Ijiri, K: 1 article (11/2003)|
01/01/1998 - "We used the RIA to assess the i.v. pharmacokinetics of LY309887 in both patients with metastatic cancer and dogs. "
01/15/2009 - "5,10-Methenyltetrahydrofolate synthetase activity is increased in tumors and modifies the efficacy of antipurine LY309887."
01/01/2000 - "In conclusion, cellular ATP depletion induced by LY309887 can be used to predict growth inhibition and cytotoxicity in human tumor cells."
01/01/1998 - "Single equimolar i.v. doses of [14C]LY309887 and [14C]lometrexol were administered to C3H mammary tumor bearing mice on SD or LFD, and the disposition of these compounds was quantitated using whole-body autoradiography. "
01/01/1996 - "LY309887 is a second generation GARFT inhibitor with biochemical and pharmacological properties which distinguish it from lometrexol and suggest that it will have broad antitumor activity, a different pharmacokinetic profile and produce less toxicity than lometrexol in cancer patients."
01/15/2009 - "In this study, the effect of increased MTHFS expression on the efficacy of the glycinamide ribonucleotide formyltransferase (GARFT) inhibitor LY309887 was investigated in SH-SY5Y neuroblastoma. "
01/15/2009 - "SH-SY5Y neuroblastoma with increased MTHFS expression displayed a 4-fold resistance to the GARFT inhibitor LY309887, but did not exhibit resistance to the thymidylate synthase inhibitor Pemetrexed. "
01/01/1996 - "Lometrexol and LY309887 were potent cytotoxic compounds against the human leukemia cell line CCRF-CEM with IC50's of 2.9 nM and 9.9 nM, respectively. "
04/01/1999 - "The current discussion is focused on studies using CCRF-CEM leukemia cells that were designed to compare and contrast mechanisms of action of the antifolates methotrexate, which is primarily a dihydrofolate reductase inhibitor, raltitrexed, a thymidylate synthase inhibitor, LY309887, a glycinamide ribonucleotide formyltransferase inhibitor, and MTA (multitargeted antifolate), which is a novel antifolate antimetabolite. "
|3.||raltitrexed (D 1694)
|7.||Folic Acid Antagonists
|9.||Tetrahydrofolate Dehydrogenase (Dihydrofolate Reductase)
|10.||Folic Acid (Vitamin M)
|1.||Heterologous Transplantation (Xenotransplantation)